文献速递慢性肾脏病肾小球疾病肾血管病与高血压

心肾联合治疗资格与可预防死亡的微观模拟研究

A Microsimulation of Eligibility for Cardiorenal Combination Treatment and Potential Deaths Averted.
PubMed 文献 · J Am Soc Nephrol · 2026-10-09

基于NHANES 2007-2016和2017-2020数据的微观模拟研究,评估RASi、SGLT2i、GLP1RA和nsMRA联合治疗资格及对死亡的影响。在8152名成人中,15%患2型糖尿病,14%患CKD,5%两者兼有。RASi+SGLT2i双联资格最高(总体15%),三联RASi+SGLT2i+GLP1RA资格11%,四联4%;三联较双联可预防约2倍的全因和心血管死亡。

要点

  • RASi+SGLT2i双联治疗资格最高,总体15%,DKD亚组84%。
  • 三联RASi+SGLT2i+GLP1RA总体资格11%,DKD亚组83%。
  • 三联治疗较双联可预防约2倍的全因和心血管死亡。

核心结论

  • 在心肾保护治疗联合使用的模拟假设下,联合治疗资格普遍,尤其在2型糖尿病和/或CKD成人中。

研究设计与样本

  • 微观模拟研究,使用NHANES 2007-2016和2017-2020数据,共8152名成人。
  • 模型纳入RASi、SGLT2i、GLP1RA和nsMRA对eGFR、UACR和血钾的急性治疗效应。
  • 根据73条临床实践指南推荐和近期临床试验入选标准评估联合治疗资格。

主要发现

  • 8152名成人中,15%患2型糖尿病,14%患CKD,5%患糖尿病合并CKD。
  • 全体美国成人中,19%接受RASi治疗,1%接受SGLT2i,1%接受GLP1RA,无人接受nsMRA。
  • 双联治疗资格最高为RASi+SGLT2i,美国总体人群15%符合(糖尿病亚组70%,CKD亚组50%,DKD亚组84%)。
  • 三联治疗资格最高为RASi+SGLT2i+GLP1RA,总体11%(糖尿病亚组69%,CKD亚组33%,DKD亚组83%)。
  • 四联治疗资格总体4%(糖尿病亚组22%,CKD亚组17%,DKD亚组40%)。

关键数值与推荐

  • 双联RASi+SGLT2i资格:总体15%,糖尿病亚组70%,CKD亚组50%,DKD亚组84%。
  • 三联RASi+SGLT2i+GLP1RA资格:总体11%,糖尿病亚组69%,CKD亚组33%,DKD亚组83%。
  • 四联治疗资格:总体4%,糖尿病亚组22%,CKD亚组17%,DKD亚组40%。

临床怎么用

  • 在2型糖尿病和/或CKD成人中,应评估心肾保护治疗联合使用的资格。
  • RASi+SGLT2i双联治疗资格人群广泛,可优先考虑。
  • 三联RASi+SGLT2i+GLP1RA虽资格较低,但可能带来更大死亡预防获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical guidelines recommend combined use of renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP1RA) and nonsteroidal mineralocorticoid receptor antagonists (nsMRA) to reduce cardiorenal risk. However, eligibility for combination treatment and the potential effects of implementation on preventing mortality remain unclear. METHODS: We conducted a microsimulation study using data from the National Health and Nutrition Examination Survey (NHANES 2007-2016 and 2017-2020). The model incorporated acute treatment effects of RASi, SGLT2i, GLP1RA, and nsMRA on estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (UACR), and serum potassium. Eligibility for combination treatment was assessed for each participant according to 73 clinical practice guideline recommendations and inclusion criteria from recently published clinical trials. Primary outcomes included: 1) the percentage of participants eligible for single or combination treatment with RASi, SGLT2i, GLP1RA, and nsMRA, and 2) the projected potential number of annually averted all-cause and cardiovascular deaths. RESULTS: Of 8,152 adults, 15% had type 2 diabetes (DM), 14% had chronic kidney disease (CKD) and 5% had DM and CKD (DKD). Among all U.S. adults, 19% were treated with RASi, 1% with SGLT2i, 1% with GLP1RA and none with nsMRA. The dual-therapy associated with the highest eligibility was RASi+SGLT2i, with 15% of the U.S. population eligible (DM subgroup: 70%; CKD subgroup: 50%; DKD subgroup: 84%). The triple-therapy with the highest eligibility was RASi+SGLT2i+GLP1RA, with 11% overall eligibility (DM: 69%; CKD: 33%; DKD: 83%). Eligibility for quadruple-therapy was 4% overall (DM: 22%; CKD: 17%; DKD: 40%). Based on our microsimulation model, fewer individuals with diabetes were eligible for triple-therapy with RASi+SGLT2i+GLP1RA compared to dual-therapy with RASi+SGLT2i, but triple-therapy was projected to prevent 2-fold more potential all-cause and cardiovascular deaths versus dual-therapy. CONCLUSIONS: Under the assumptions of our microsimulation model, eligibility for combined treatment with cardiorenal protective therapies was prevalent, particularly in adults with type 2 diabetes and/or CKD.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Nardone M, Faruque L, Dubrofsky L, et al. A Microsimulation of Eligibility for Cardiorenal Combination Treatment and Potential Deaths Averted. J Am Soc Nephrol. 2026. PMID: 42853614. doi:10.1681/ASN.0000001287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。